Literature DB >> 9153534

CAG repeat number governs the development rate of pathology in Huntington's disease.

J B Penney1, J P Vonsattel, M E MacDonald, J F Gusella, R H Myers.   

Abstract

We compared the number of CAG repeats, the age at death, and the severity of neuropathology in 89 Huntington's disease brains. We found a linear correlation between the CAG repeat number and the quotient of the degree of atrophy in the striatum (the brain region most severely affected in Huntington's disease) divided by age at death, with an intercept at 35.5 repeats. The largest CAG repeat length, therefore, at which no pathology is expected to develop is 35.5. These results imply that striatal damage in Huntington's disease is almost entirely a linear function of the length of the polyglutamine stretch beyond 35.5 glutamines multiplied by the age of the patient. Thus, it is predicted that the pathological process develops linearly from birth. Analysis of other measures of striatal function could test this hypothesis and might determine when treatment for CAG repeat diseases should start.

Entities:  

Mesh:

Year:  1997        PMID: 9153534     DOI: 10.1002/ana.410410521

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  213 in total

1.  Subcellular and subsynaptic localization of presynaptic and postsynaptic kainate receptor subunits in the monkey striatum.

Authors:  J Z Kieval; G W Hubert; A Charara; J F Paré; Y Smith
Journal:  J Neurosci       Date:  2001-11-15       Impact factor: 6.167

Review 2.  Differential vulnerability of neurons in Huntington's disease: the role of cell type-specific features.

Authors:  Ina Han; YiMei You; Jeffrey H Kordower; Scott T Brady; Gerardo A Morfini
Journal:  J Neurochem       Date:  2010-03-17       Impact factor: 5.372

3.  Brain metabolite alterations and cognitive dysfunction in early Huntington's disease.

Authors:  Paul G Unschuld; Richard A E Edden; Aaron Carass; Xinyang Liu; Megan Shanahan; Xin Wang; Kenichi Oishi; Jason Brandt; Susan S Bassett; Graham W Redgrave; Russell L Margolis; Peter C M van Zijl; Peter B Barker; Christopher A Ross
Journal:  Mov Disord       Date:  2012-05-30       Impact factor: 10.338

4.  Longitudinal Psychiatric Symptoms in Prodromal Huntington's Disease: A Decade of Data.

Authors:  Eric A Epping; Ji-In Kim; David Craufurd; Thomas M Brashers-Krug; Karen E Anderson; Elizabeth McCusker; Jolene Luther; Jeffrey D Long; Jane S Paulsen
Journal:  Am J Psychiatry       Date:  2015-10-16       Impact factor: 18.112

5.  Faulty neuronal determination and cell polarization are reverted by modulating HD early phenotypes.

Authors:  P Conforti; D Besusso; V D Bocchi; A Faedo; E Cesana; G Rossetti; V Ranzani; C N Svendsen; L M Thompson; M Toselli; G Biella; M Pagani; E Cattaneo
Journal:  Proc Natl Acad Sci U S A       Date:  2018-01-08       Impact factor: 11.205

6.  Octapeptide repeat insertions increase the rate of protease-resistant prion protein formation.

Authors:  Roger A Moore; Christian Herzog; John Errett; David A Kocisko; Kevin M Arnold; Stanley F Hayes; Suzette A Priola
Journal:  Protein Sci       Date:  2006-02-01       Impact factor: 6.725

7.  Glutamate uptake is reduced in prefrontal cortex in Huntington's disease.

Authors:  Bjørnar Hassel; Shoshi Tessler; Richard L M Faull; Piers C Emson
Journal:  Neurochem Res       Date:  2007-08-29       Impact factor: 3.996

8.  Genome-wide RNA interference screen identifies previously undescribed regulators of polyglutamine aggregation.

Authors:  Ellen A A Nollen; Susana M Garcia; Gijs van Haaften; Soojin Kim; Alejandro Chavez; Richard I Morimoto; Ronald H A Plasterk
Journal:  Proc Natl Acad Sci U S A       Date:  2004-04-14       Impact factor: 11.205

9.  Impairment of developmental stem cell-mediated striatal neurogenesis and pluripotency genes in a knock-in model of Huntington's disease.

Authors:  Aldrin E Molero; Solen Gokhan; Sara Gonzalez; Jessica L Feig; Lucien C Alexandre; Mark F Mehler
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-02       Impact factor: 11.205

10.  Characteristics and occurrence of speech impairment in Huntington's disease: possible influence of antipsychotic medication.

Authors:  Jan Rusz; Jiří Klempíř; Tereza Tykalová; Eva Baborová; Roman Čmejla; Evžen Růžička; Jan Roth
Journal:  J Neural Transm (Vienna)       Date:  2014-05-09       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.